Skip to main content

Research News

 

Clinical courses

 

Clinical research courses

  • Lipid profile can predict risk of diabetes and CVD decades before incidence

    Recent large population cohort analysis demonstrated that a subset of individuals at high risk for developing type 2 diabetes or cardiovascular diseases can be predicted years before disease incidence. The study is published in Plos Biology.

  • Blood pressure medication impacts brain activity

    The research team discovered that drugs used to treat blood pressure unexpectedly increase the effect of opioids that the brain naturally produces. This can fine-tune the function of a specific brain circuit and counteract the addictive properties of opiates like fentanyl, which are used to treat pain.

  • Whole-genome sequencing reveals new secrets about killer fungus

    New research from the University of Exeter reports the largest ever whole-genome sequencing project for the potentially fatal yeast infection Candida glabrata from hospitals across Scotland.

  • Ayurvedic BGR-34 therapy is effective in the treatment of diabetes, says research

    Recent research reported that Ayurvedic medicine BGR-34 is effective in reducing high blood sugar levels and this reflects that the BGR-34 therapy is a more effective drug in the treatment of diabetes.

  • Omalizumab provides benefit to patients with allergic asthma, regardless of BMI

    Researchers find out in a recent study that omalizumab provides benefit to patients with moderate to severe allergic asthma, regardless of body mass index.

  • Bharat Biotech to work on TB vaccine

    Bharat Biotech is in the process of bringing out a vaccine against tuberculosis and soon the firm will sign a MoU with another firm for technology.

    "Our honourable Prime Minister has got an agenda of 2025 for the eradication of tuberculosis. I think we are in that direction. But we don't have the technology so we are partnering with somebody else. On that matter we should be announcing soon," Krishna Ella, Chairman and Managing Director said in BioAsia 2022.

  • Repurposing FDA-approved drugs may help combat COVID-19

    Several FDA-approved drugs including for type 2 diabetes, hepatitis C and HIV significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Specifically, the team found that these drugs inhibit certain viral enzymes, called proteases, that are essential for SARS-CoV-2 replication in infected human cells.

  • Experimental combinatorial therapy eliminates an incurable brain tumour

    A study recently accepted for publication in The Journal of Clinical Investigation describes a new and effective therapy to treat glioblastoma: the concomitant use of ADI-PEG20 together with focal brain radiotherapy. This double treatment completely eliminated the tumour in the animal models used in the study. This study was carried out by researchers from the Institute of Biomedicine of Seville: Dr. Manuel Sarmiento Soto, Dr. Juan García Revilla, and Dr. José Luis Venero, in collaboration with Dr. Nabil Hajji and Dr. Nel Syed of Imperial College London.

  • Development of nanoengineered bacteria for cancer optotheranostics

    There is substantial interest regarding the understanding and designing of nanoengineered bacteria to combat various fatal cancerous diseases. However, conventional nanotechnological approaches adopt genetic manipulation for attenuating and improving the efficacy of bacteria. In addition, complicated chemical reactions were essential in the previous approaches.

  • NIAB discover potential biomarker for Japanese encephalitis virus

    NIAB discover potential biomarker, NS 1 protein for Japanese encephalitis virus. Non-Structural 1 protein, a potential diagnostic biomarker for Japanese encephalitis virus. A diagnostic biomarker refers to a biological parameter that aids the diagnosis of a disease and may serve in determining disease progression or success of treatment.

Subscribe to Research News